Trial Profile
Phase Ib/II Trial Evaluating the Safety, Tolerability and Immunological Activity of Durvalumab (MEDI4736) (Anti-PD-L1) Plus Tremelimumab (Anti-CTLA-4) Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colon cancer; Colorectal cancer; Rectal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms MEDITREME
- 23 Sep 2023 Results assessing the immune response observed following immune monitoring of patients before and during MEDITREME trial, presented at the CRI-ENCI-AACR: 7th Annual International Cancer, Immunotherapy Conference.
- 01 Aug 2023 Results published in the Nature Medicine
- 09 Feb 2023 Status changed from recruiting to completed.